ADO

8.70%

2.1¢ anteotech ltd

COVID Testing, page-6

First 6 Last

Share
Profile

Follow
MindGuy

62 Posts.

41

01/06/21

19:54

Post #: 53574800
Share

Originally posted by herro: ↑

I haven’t posted on ADO before, although I first invested in 2010 when commercialdeals were said by management to be “incredibly close” and you’d need to be a long termer to know what that means.

I’ve been trying to keep an eye on ADO’s competition in the Covid ART sector, but with more companies regularly entering the market, it’s not been an easy task.

I suspect it’s probably been discussed here, but a couple of days ago The Lancet published the results of a comparative study by the UK Lateral Flow Oversight Group of 64 Covid rapid antigen lateral flow immunoassay devices, (selected from 132 submissions).

Definitely worth a look if you haven’t seen it already.

https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00204-2/fulltext

There’s a level of complexity in the document, but it seems to me the bar for selection must have been set fairly low.

As a result, false positives and negatives, high ‘kit failure’ rates, lack of independent validation and ‘variable performance’ were common areas of concern in the study.

In the end the review found only 4 of the 64 had “desirable performance characteristics”. These were offerings from orient Gene, Deepblue, Abbott and Innova.

So based on results already available from Doherty institute studies, it’s fairly clear to me that ADO appears to have a test superior to the vast majority of other devices on offer. Suggestions of ‘Top 5’ certainly don’t seem unrealistic. Saliva results will be the key.

So while ADO is a latecomer to the game, if our UK results are up to the standard many here are hoping for, imo we certainly seem to have a competitive commercial shot. Access to key decision makers, effective tendering, attractive pricing, consistent high quality manufacturing and efficient lines of distribution will be critical.

So with a sense of deja vu, after 11 years, I’ve got the same feeling.

Incredibly close!

With obvious bias.

Herro

Expand

Thank you for this post. I've been looking for data like this.

ADO Price at posting: 31.5¢ Sentiment: Hold Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

BUX

Buxton projects new graphite province discovery at WA Narryer play

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

There are more pages in this discussion • 116 more messages in this thread...

First 6 Last

Add ADO (ASX) to my watchlist

(20min delay)
Last 2.1¢		Change -0.002(8.70%)		Mkt cap ! $52.28M

Open	High	Low	Value	Volume
2.2¢	2.2¢	2.1¢	$20.83K	964.6K

Buyers (Bids)

No.	Vol.	Price($)
4	2247357	2.1¢

Sellers (Offers)

Price($)	Vol.	No.
2.2¢	164375	3

View Market Depth

No.	Vol.	Price($)
2	739397	0.021
9	1445497	0.020
10	2127381	0.019
4	1601447	0.018
3	1564748	0.017

Price($)	Vol.	No.
0.023	642868	9
0.024	741966	3
0.025	478846	7
0.026	83915	2
0.027	250000	1

Last trade - 16.10pm 04/10/2024 (20 minute delay)

ADO (ASX) Chart

COVID Testing, page-6

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Buxton projects new graphite province discovery at WA Narryer play

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

BCI reaches close of funding facility for salt-first part of Mardie project

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

COVID Testing, page-6

Top Stories

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Buxton projects new graphite province discovery at WA Narryer play

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

BCI reaches close of funding facility for salt-first part of Mardie project

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News